SparingVision Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 39

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $40.3M

  • Investors
  • 17

SparingVision General Information

Description

Developer of a medical therapy designed to treat retinal diseases and vision loss disorders. The company's offerings include a drug candidate to treat retinitis pigmentosa, the most frequent inherited retinal degeneration that can progress to blindness and affects many patients worldwide, intending to preserve and restoring visual function, enabling biotechnology and healthcare organizations to create treatments for inherited and degenerative retinal conditions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5/7 Avenue Percier
  • CS40230
  • 75008 Paris
  • France
+33 01
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 5/7 Avenue Percier
  • CS40230
  • 75008 Paris
  • France
+33 01

SparingVision Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SparingVision Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC 30-Jun-2025 $40.3M Completed Generating Revenue
11. Accelerator/Incubator 01-Jan-2024 Completed Generating Revenue
10. Later Stage VC 01-Oct-2023 Completed Generating Revenue
9. Accelerator/Incubator Completed Generating Revenue
8. Later Stage VC (Series B) 12-Sep-2022 Completed Generating Revenue
7. Later Stage VC 13-Oct-2021 Completed Generating Revenue
6. Early Stage VC (Series A) 21-Oct-2020 Completed Generating Revenue
5. Grant 01-Oct-2019 Completed Generating Revenue
4. Accelerator/Incubator 09-Jul-2019 $2.82M $20M Completed Generating Revenue
3. Grant 01-Jan-2017 $316K $17.1M Completed Startup
To view SparingVision’s complete valuation and funding history, request access »

SparingVision Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class B Shares
Class B Shares
A2 Shares
A2 Shares
Series A 61,426 $1.151041 $140.54 $140.54 1x $140.54 3.89%
A Shares 80,000 $1.151041 $115.1 $115.1 1x $115.1 5.07%
To view SparingVision’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

SparingVision Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a medical therapy designed to treat retinal diseases and vision loss disorders. The company's offerings inc
Drug Discovery
Paris, France
39 As of 2026

Newport Beach, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SparingVision Competitors (1)

One of SparingVision’s competitors is jCyte, a Venture Capital-Backed company based in Newport Beach, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
jCyte Venture Capital-Backed Newport Beach, CA
You’re viewing 1 of 1 competitors. Get the full list »

SparingVision Patents

SparingVision Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260193723-A1 Methods of detecting replication competent aav Pending 18-Oct-2024
WO-2026083130-A1 Methods of detecting replication competent aav Pending 18-Oct-2024
AU-2023362592-A1 Compositions and methods for treating retinal degenerative disorders Pending 20-Oct-2022
EP-4605537-A1 Compositions and methods for treating retinal degenerative disorders Pending 20-Oct-2022
WO-2024084075-A1 Compositions and methods for treating retinal degenerative disorders Inactive 20-Oct-2022 A61K48/005
To view SparingVision’s complete patent history, request access »

SparingVision Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SparingVision Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
La French Tech Accelerator/Incubator
Inserm Transfert VC-Backed Company Minority
Retinal Degeneration Fund Not-For-Profit Venture Capital Minority
Intellia Therapeutics Corporation Minority
4BIO Capital Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

SparingVision Investments & Acquisitions (2)

SparingVision’s most recent deal was a Early Stage VC with Tenpoint Therapeutics for . The deal was made on 12-Jul-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Tenpoint Therapeutics 12-Jul-2023 Early Stage VC Drug Discovery
Gamut Therapeutics 20-Apr-2021 Merger/Acquisition Drug Discovery
To view SparingVision’s complete investments and acquisitions history, request access »

SparingVision FAQs

  • When was SparingVision founded?

    SparingVision was founded in 2016.

  • Where is SparingVision headquartered?

    SparingVision is headquartered in Paris, France.

  • What is the size of SparingVision?

    SparingVision has 39 total employees.

  • What industry is SparingVision in?

    SparingVision’s primary industry is Drug Discovery.

  • Is SparingVision a private or public company?

    SparingVision is a Private company.

  • What is the current valuation of SparingVision?

    The current valuation of SparingVision is .

  • What is SparingVision’s current revenue?

    The current revenue for SparingVision is .

  • How much funding has SparingVision raised over time?

    SparingVision has raised $205M.

  • Who are SparingVision’s investors?

    La French Tech, Inserm Transfert, Retinal Degeneration Fund, Intellia Therapeutics, and 4BIO Capital are 5 of 17 investors who have invested in SparingVision.

  • Who are SparingVision’s competitors?

    jCyte is a competitor of SparingVision.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process